Apr 22, 2025; Indianapolis, Indiana, USA; Milwaukee Bucks forward Bobby Portis (9) celebrates a made basket during game two of first round for the 2024 NBA Playoffs against the Indiana Pacers at Gainbridge Fieldhouse. Mandatory Credit: Trevor Ruszkowski-Imagn Images Milwaukee Bucks forward Bobby Portis has declined his player option and will sign a three-year, $44 million contract to stay with the team, multiple media outlets reported on Sunday.
Portis, 30, had until Sunday to decide on the player option worth $13.4 million. The new deal includes a player option in the final season of 2027-28, the Milwaukee Journal-Sentinel reported.
Portis averaged 13.9 points, 8.4 rebounds and 2.1 assists in only 49 games (seven starts) last season, when the NBA suspended him 25 games without pay for violating the league’s anti-drug policy.
The NBA said Portis tested positive for the drug Tramadol, a medication used to treat severe pain among adults. Portis’ agent, Mark Bartelstein of Priority Sports, told ESPN that his client confused Tramadol with an approved pain medication called Toradol.
Portis has averaged 13.6 points, 8.3 rebounds and 1.4 assists in 339 regular-season games (99 starts) over five seasons in Milwaukee, where he has been a valued reserve voted third for the NBA Sixth Man of the Year Award in both 2023 and 2024. He also was a member of the Bucks’ league championship squad in 2021.
For his career, Portis is averaging 12.0 points, 7.2 rebounds and 1.3 assists in 654 regular-season games (153 starts) for the Chicago Bulls (2015-19), Washington Wizards (2019), New York Knicks (2019-20) and Bucks (2020-present).
–Field Level Media
